Otsenka effektivnosti pantoprazola v sostave kompleksnoy terapii dekompensirovannogo tsirroza pecheni, oslozhnennogo erozivno-yazvennym porazheniem gastroduodenal'noy zony


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the results of a clinical trial, which enrolled 34 patients with decompensated liver cirrhosis of different etiologies, with erosive-ulcerative lesions of the stomach and duodenum. All patients received proton pump inhibitor pantoprazole (Nolpaza) at a dose of 20 mg per day for 16 days as a part of complex therapy. The data demonstrate the high efficiency of pantoprazole in the complex therapy of liver cirrhosis. Complete healing of erosive-ulcerative lesions of the mucous membrane was observed in 29 (85,3 %) patients; 3 (8,9 %) patients had significant improvement in endoscopic picture on the background of general well-being mend.

Full Text

Restricted Access

References

  1. Губергриц Н.Б., Лукашевич Г.М., Загоренко Ю.А. Гепатогенные гастропатии и гепатогенные язвы: старая история, которая остается вечно новой// Мистецтво л'кування 2005. № 3. С. 8-12.
  2. Ханевич М.Д., Кошевой А.П. Лечение при язвенных кровотечениях у больных с циррозом печени и портальной гипертензией // Вестн. хирургии им. И.И. Грекова 2000. № 2. С. 27-30.
  3. Логинов А.С., Кондашева З.Д., Иоффе В.С. О "гепатогенных" язвах желудка и двенадцатиперстной кишки // Актуальные вопросы гастроэнтерологии: Сб. тр. М., 1974. С. 251-55.
  4. Шерлок Ш. Дж., Дули. Заболевания печени и желчных путей (пер. с англ). М., 1999. 860 с.
  5. McCormack T, Sims J. Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy? Gut 1985;26: 1226-32.
  6. Primignani M, Carpinelli L, Preatoni P. Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. The New Italian Endoscopic Club for the study and treatment of esophageal varices (NIEC). Gastroenterology 2000;119:181-87.
  7. Misra V, Misra SP, Dwivedi M. Thickened gastric mucosal capillary wall: a histological marker for portal hypertension. Pathology 1998;30(1):10-3.
  8. Gupta R. Gastric mucosal blood flow and hepatic perfusion index in patients with portal hypertensive gastropathy. J Gastroenterol Hepatol 1998;13(9):921 -26.
  9. Хомерики С.Г., Мельникова С.В., Обуховский Б.И. Клинико-морфологические проявления гастропатии у больных с портальной гипертензией // Гепатология 2005. № 1. С. 8-15.
  10. Mercel C, Schipilliti M. Portal hypertension and portal hypertensive gastropathy in liver cirrhosis: a hemodinamic study. Dig Liver Dis 2003;4:269-74.
  11. Stewart CA, Sanyal AJ. Grading portal gastropathy: validation of a gastropathy scoring system. Am J Gastroenterol 2003;8: 1758-65.
  12. Крылов Н.Н. Кровотечения из верхних отделов пищеварительного тракта: причины, факторы риска, диагностика, лечение // Рос. журн. гастроэнтерологии, гепатологии, колопроктологии 2001. № 2. С. 76-87.
  13. Подымова С.Д. Болезни печени: Рук-во для врачей. М., 2005. 768 с.
  14. Юдин А.Ю., Яковенко Э.П. Состояние слизистой желудка и двенадцатиперстной кишки у больныхсхроническойалкогольной интоксикацией // Практикующий врач 2002. № 1. С. 56-7.
  15. Hayes PC, Simpson KJ, Garden OJz. Liver and biliary tract disease. In: Davidson's principles & practice of medicine. 19th ed. London, Churchill Livingstone 2002:831 -88.
  16. Hayes PC, Collier JD, Chapman RW. Liver and biliary tract disease. In: Davidson's principles & practice of medicine. 20th ed. London, Churchill Livingstone 2006:935-97.
  17. Burak KW, Lee SS, Beck PL. Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome. Gut 2001;49:866-72.
  18. Bilal А, et al. Frequency of peptic ulcer in patients having decompensated cirrhosis of liver. APMC 2008;2( 1 ):35-40.
  19. Francesca Lodato, et all. Proton pump inhibitors in cirrhosis: Tradition or evidence based practice? World J Gastroenterol 2008;14(19):2980-85.
  20. Trikudanathan1 G, Israel J, Cappa J, O'Sullivan DM. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis. International Journal of Clinical Practice 2011;65(6):674-78.
  21. Auroux J, lamarque D, Roudot TF, et al. Gastroduodenal ulcer and erosions are related to portal hypertensive gastropathy and recent alcohol intake in cirrhotic patients. Dig Dis Sci 2003;48(6): 1118-23.
  22. Shahin WA. Low incidence of helicobacter pylori infection in patients with duodenal ulcer and chronic liver disease. Ed. WA Shahin, EZ Abdel-Baset. Scand J Gastroenterol 2001;36(5):479-84.
  23. Яковенко Э.Л., Яковенко А.В., Агафонова И.А. и др. Пептические язвы, патогенетические подходы к терапии // Фарматека 2008. № 13. С. 62-7.
  24. Pan W J, et al. Lack of a pharmacokinetic interaction between lansoprazole or panto-prazole and theophylline. Aliment. Pharmacol Ther 2000;14(3):345-52.
  25. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors. Drug Safety 2006;29(9):769-84.
  26. Andersson T, Cederberg C, Heggelund A. The pharmacokinetics of single and repeated once daily dose of 10, 20 and 40 mg omeprazole as enteric coated granules. Drug Invest 1991;3:45-52.
  27. Scott LJ, Dunn CJ, Mallarkey G, et al. Esomeprazole: a review of its use in the management of acid-related disorders in US. Drugs 2002;62(7): 1091-118.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies